International Clinical Trial: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Geneva, June 4 -- International Clinical Trials Registry received information related to the study (NCT06987734) titled 'Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients' on May 16.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Pulmonary Hospital, Shanghai, China

Condition: Lung Cancer (NSCLC)

Intervention: Drug: Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: May 31, 2025

Target Sample Si...